Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$75.89 USD

75.89
5,193,831

-0.03 (-0.04%)

Updated Jun 5, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (91 out of 248)

Industry: Medical - Products

Better trading starts here.

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

BD (BDX) Inks Buyout Deal to Expand Smart Connected Care Suite

BD's (BDX) latest agreement is likely to unlock new future value-creation opportunities and expand its portfolio of smart connected care solutions.

Glaukos (GKOS) Gains 40.4% YTD: What's Driving the Rally?

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Stryker's (SYK) LIFEPAK 35 to Offer Advanced Monitoring System

Stryker (SYK) announces the launch of LIFEPAK 35 monitor/defibrillator, which is likely to aid emergency responders to reduce cognitive load during demanding situations by improving workflow.

Stryker's (SYK) Acquisition of Artelon Set to Expand Its Market

Stryker (SYK) announces the signing of the definitive agreement to acquire a privately held company, Artelon, to strengthen its foothold in the soft tissue fixation market.

Here's Why You Should Retain Nevro (NVRO) Stock for Now

Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.

HealthEquity (HQY) Q1 Earnings Surpass Estimates, Margins Up

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the first quarter of fiscal 2025.

Inari's (NARI) Expanding Product Portfolio Offsets Competition

Inari's (NARI) VTE products are driving its top line on the back of robust adoption. The company is expanding in additional indications to fuel growth and fight competition.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Three Reasons to Retain BD (BDX) Stock in Your Portfolio Now

BD's (BDX) robust product portfolio raises optimism about the stock.

Patterson Companies' (PDCO) New Launch to Boost Patient Service

Patterson Companies' (PDCO) Patterson CarePay+ is likely to improve overall patient care and streamline practice operations.

ClearPoint's (CLPT) New Products to Boost Neurosurgical Segment

ClearPoint (CLPT) announces the full market release of the SmartFrame OR platform, intended for performing DBS, and Prism Neuro Laser Therapy System for providing thermal therapy.

Boston Scientific (BSX) Rises Yet Lags Behind Market: Some Facts Worth Knowing

In the latest trading session, Boston Scientific (BSX) closed at $75.57, marking a +0.76% move from the previous day.

Envista (NVST) Down 4.7% Since Last Earnings Report: Can It Rebound?

Envista (NVST) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Surmodics (SRDX) Enters Deal to be Acquired by GTCR for $627M

Surmodics (SRDX) enters a definitive agreement to be acquired by renowned private equity company GTCR at an estimated total equity valuation of $627 million.

DaVita (DVA) Hits 52-Week High: What's Aiding the Stock?

Investors are optimistic about DaVita's (DVA) strength in kidney care.

Veeva Systems (VEEV) Q1 Earnings Beat Estimates, Margins Up

Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performance by both segments.

Here's Why You Should Add Lantheus (LNTH) to Your Portfolio Now

Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.

Stryker (SYK) to Launch Gamma4 Hip Fracture System in Europe

Stryker (SYK) announces plan to launch its Gamma4 Hip Fracture Nailing System in Europe. It completes initial surgeries successfully.

Reasons Why You Should Retain Avantor (AVTR) Stock for Now

Avantor's (AVTR) strong product portfolio raises optimism about the stock.

Stryker (SYK) Issues Safety Notice for Its Total Knee System

Stryker (SYK) issues urgent field safety notice for the Mako Total Knee systems, the application software of which generated software error codes. The company also shares risk mitigation steps.

Reasons to Retain PacBio (PACB) Stock in Your Portfolio

PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.

Intuitive Surgical (ISRG) Stock Gains 20% YTD: Here's Why

Intuitive Surgical (ISRG) shares gain on the back of growth in the da Vinci treatment volume and raised procedure prices.

HAE or BSX: Which Is the Better Value Stock Right Now?

HAE vs. BSX: Which Stock Is the Better Value Option?

ResMed (RMD) Up 16.3% Since Last Earnings: Will it Continue?

Investors are optimistic about ResMed (RMD) led by strong growth in the U.S. mask and accessories business and its cloud-connected platforms.

Inari Medical (NARI) Sues Truvic on Patent Infringement

Inari Medical (NARI) files a patent infringement lawsuit against Imperative Care and its subsidiary Truvic over intentionally copying and overlapping the designs of Inari Medical's products.